Vinpocetine

Supplements · Nootropics · Supplement, Typed Supps

A lab-modified plant compound sold as a brain and circulation supplement, but one the FDA has said shouldn’t legally be sold as a supplement in the US — partly because of pregnancy-related safety concerns seen in animal studies.

Stage by stage

Intake (Tablet or capsule): Taken orally in milligram doses.
Absorption (Gut): Absorbed into the bloodstream.
Bloodstream (Circulates): Crosses the blood-brain barrier and affects blood vessels and platelets.
Brain (Proposed vasodilation/neuronal effects): Proposed to affect blood flow and neuronal activity, though human cognitive benefit remains unproven.

What the evidence supports

Improving cognitive function or outcomes in dementia or cognitive impairment — insufficient evidence. A Cochrane review of randomized trials in dementia patients found the available studies inadequate to support vinpocetine’s use, despite some individual trials suggesting benefit on global clinical impression measures. More recent reviews describe the overall trial history as largely inconclusive.
Benefiting acute ischemic stroke recovery when given intravenously — limited evidence. Some larger studies, mostly from China using IV administration as adjunctive stroke therapy, report neurological benefits, but this differs substantially from oral supplement use and hasn’t been established as a supplement-level benefit for the general public.
Evidence on US regulatory status as a legal dietary supplement ingredient — insufficient evidence. In 2016 the FDA published a Federal Register notice concluding vinpocetine does not meet the legal definition of a dietary ingredient and is excluded from the dietary supplement definition, because it was already under investigation as a new drug before being marketed as a supplement — the same legal pathway issue affecting noopept. The FDA’s notice also cited animal reproductive toxicity data raising concerns about fetal harm.
Evidence on Reproductive safety, specifically miscarriage or fetal harm risk — limited evidence. Animal studies cited by the FDA found evidence of decreased fetal weight and increased pregnancy loss at vinpocetine exposures relevant to human supplement use, which was a central part of the agency’s 2016 safety rationale, though this hasn’t been directly confirmed in human pregnancy data.

Typical dose

Clinical trials have used roughly 15–60mg/day in divided doses; supplement products commonly suggest 10–30mg/day, but there is no regulator-validated standard dose in the US.

Upper limit: No established UL; the FDA’s 2016 notice reflects a safety concern at supplement-relevant doses, not just very high ones.

Timing

No FDA-endorsed dosing guidance exists given its regulatory status.

Time to effect

Unclear: The Cochrane review of dementia trials found the evidence inadequate to establish a reliable timeline or magnitude of cognitive benefit.

Common myth

“Vinpocetine is a well-studied, legal brain supplement.” In reality: The FDA has formally proposed that vinpocetine does not meet the legal definition of a dietary supplement ingredient in the US, and separately flagged real animal data on fetal harm and pregnancy loss as part of that safety review — a genuinely significant regulatory and safety fact, not a technicality.